Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01570
|
|||||
| Drug Name |
Homocamptothecin
|
|||||
| Synonyms |
homocamptothecin; UNII-5B3LFU8GLM; 5B3LFU8GLM; E-Homocamptothecin; E-Homocamptothecine; (20R)-Homocamptothecin; E-Homocamptothecin, (R)-; CHEMBL74190; SCHEMBL5860320; PAEZRCINULFAGO-OAQYLSRUSA-N; ZINC840834; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (5R)-; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (R)-
|
|||||
| Indication | Cancer [ICD11: 2A00-2F9Z] | Preclinical | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H18N2O4
|
|||||
| Canonical SMILES |
CCC1(CC(=O)OCC2=C1C=C3C4=NC5=CC=CC=C5C=C4CN3C2=O)O
|
|||||
| InChI |
InChI=1S/C21H18N2O4/c1-2-21(26)9-18(24)27-11-14-15(21)8-17-19-13(10-23(17)20(14)25)7-12-5-3-4-6-16(12)22-19/h3-8,26H,2,9-11H2,1H3/t21-/m1/s1
|
|||||
| InChIKey |
PAEZRCINULFAGO-OAQYLSRUSA-N
|
|||||
| CAS Number |
CAS 186669-19-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 362.4 | Topological Polar Surface Area | 79.7 | ||
| Heavy Atom Count | 27 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
0.7
|
|||||
| PubChem CID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res. 1999 Jun 15;59(12):2939-43. | |||||
| 2 | ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007 Mar;26(1):39-57. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.